Actavis has launched Valaciclovir in Switzerland on day one after the patent expired on 27 June. Valaciclovir is used to treat herpes virus infections.

Valaciclovir Actavis has already been launched in a number of markets í Europe, including France and the UK, and will soon be entering other European markets. In Switzerland, it was launched under the Actavis brand as well as by customers of Medis - Actavis’ Third-party sales division.

Valaciclovir is marketed by GlaxoSmithKline under the brand names Valtrex® / Zelitrex®. The equivalent generic drug from Actavis is available in Switzerland in 500mg tablets.

Valaciclovir (also spelt valacyclovir) is used to treat herpes virus infections, including cold sores, shingles and genital herpes in adults as well as chickenpox and cold sores in children.

Valaciclovir Actavis was developed by Actavis R&D and is manufactured by Actavis in Iceland.